NewAmsterdam Pharma Company N.V. Interest Expense On Lease Liabilities
NewAmsterdam Pharma Company N.V. (NAMS) reported Interest Expense On Lease Liabilities of EUR 9.00 thousand for the 12-month period ending 2022-12-31, per its 20-F/A filed 2024-10-28.
Financial Statements › Expense Statement › Interest Expense
ifrs-full:InterestExpenseOnLeaseLiabilities · last filed 2024-10-28
| Period end | Interest Expense On Lease Liabilities 12 month |
|---|---|
| 2022-12-31 | 9.00K EUR 20-F/A · filed 2024-10-28 |
| 2021-12-31 | 2.00K EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |